Most people approach fat loss with a single compound and hope for the best. That approach leaves results on the table. A growing body of preclinical and early-phase clinical evidence points toward a different strategy: combining agents that act through distinct, complementary metabolic pathways so the net effect exceeds what any single molecule delivers alone.

This guide breaks down a three-peptide protocol built around Retatrutide, MOTS-C, and NAD+ — what each compound does at the cellular level, why they work better together, how to structure dosing, and what realistic timelines look like.

Why a Multi-Target Approach Outperforms Monotherapy

Adipose tissue is not a passive storage depot. It is an endocrine organ regulated by appetite signaling, insulin sensitivity, mitochondrial bioenergetics, and cellular energy sensing (AMPK/mTOR balance). Targeting only one node — say, appetite — leaves the other nodes unaddressed. Metabolic adaptation ("plateaus") happens precisely because the body compensates through the untouched pathways.

A well-designed stack hits three independent axes simultaneously:

1. Central appetite and incretin signaling — reducing caloric intake at the hypothalamic level.
2. Peripheral energy expenditure — forcing mitochondria to burn more substrate per unit time.
3. Cellular repair and NAD+ repletion — keeping the metabolic machinery running at full capacity as the body shifts into a catabolic state.

When all three axes fire in parallel, the plateau window shrinks and lean-mass preservation improves — exactly the combination serious practitioners are after.

Retatrutide: The Triple-Agonist Anchor

Retatrutide (LY-3437943) is a GIP/GLP-1/glucagon receptor tri-agonist developed by Eli Lilly. Phase 2 trial data published in the New England Journal of Medicine showed mean body-weight reductions up to 24.2 % over 48 weeks at the highest dose — numbers that surpassed both semaglutide and tirzepatide in comparable timeframes.

The pharmacology is straightforward but powerful:

• GLP-1 agonism: suppresses appetite via hypothalamic satiety centers, slows gastric emptying, and improves beta-cell glucose responsiveness.
• GIP agonism: potentiates insulin secretion in a glucose-dependent manner and appears to amplify the central appetite effects of GLP-1.
• Glucagon receptor agonism: increases hepatic lipid oxidation and energy expenditure — the differentiator that pushes retatrutide beyond dual-agonist compounds.

That glucagon component is the key. Glucagon activates hepatic fatty-acid oxidation and thermogenesis, effectively turning the liver into an additional fat-burning engine. No currently approved GLP-1 mono-agonist or GIP/GLP-1 dual-agonist does this.

Typical research protocols use escalating subcutaneous doses starting at 1 mg/week and titrating up to 8–12 mg/week over 12–16 weeks. Nausea management during escalation is the primary practical concern.

MOTS-C: The Mitochondrial Exercise Mimetic

While Retatrutide works top-down (brain and liver), MOTS-C works bottom-up — directly inside the mitochondria of skeletal muscle and adipose tissue.

MOTS-C is a 16-amino-acid peptide encoded by the mitochondrial genome (12S rRNA gene). Its mechanism centers on AMPK activation and downstream metabolic reprogramming:

• Activates AMPK in skeletal muscle, stimulating glucose uptake and fatty-acid oxidation independently of insulin.
• Upregulates the folate–methionine cycle, shifting one-carbon metabolism toward purine synthesis — a hallmark of cells transitioning from storage mode to active energy production.
• Improves insulin sensitivity at the receptor level, lowering fasting glucose and HOMA-IR in preclinical models of diet-induced obesity.
• Reduces visceral adiposity preferentially over subcutaneous fat — a pattern that mirrors the metabolic benefits of exercise.

Researchers have called MOTS-C an "exercise mimetic" because it reproduces several of the metabolic signatures of endurance training: enhanced AMPK tone, improved glucose disposal, and increased mitochondrial fatty-acid oxidation capacity. For individuals who cannot train at high volumes due to the caloric restriction imposed by Retatrutide, MOTS-C provides a pharmacological safety net for maintaining metabolic rate.

Standard research dosing is 5 mg subcutaneously, 3–5 times per week. Some protocols align MOTS-C injections with training days to amplify the synergy with exercise-induced AMPK activation.

NAD+: The Metabolic Currency No One Can Afford to Deplete

Caloric restriction increases NAD+ demand. Every unit of fatty acid that enters beta-oxidation requires NAD+ as a cofactor. Every cycle of the citric acid (TCA/Krebs) cycle generates NADH that must be reoxidized. When NAD+ availability drops, mitochondrial output drops with it — and the body downregulates energy expenditure to compensate. This is one of the molecular roots of the weight-loss plateau.

NAD+ supplementation directly replenishes the intracellular NAD+ pool, keeping the mitochondrial electron-transport chain running at capacity even under caloric deficit conditions. The downstream effects include:

• Sirtuin activation (SIRT1, SIRT3): sirtuins are NAD+-dependent deacetylases that regulate mitochondrial biogenesis, fatty-acid oxidation, and inflammatory tone. Higher NAD+ = higher sirtuin activity = more efficient fat oxidation.
• PARP-1 support: DNA repair via PARP enzymes is NAD+-dependent. Caloric restriction combined with exercise increases oxidative stress and DNA damage; adequate NAD+ ensures repair pathways remain functional.
• Circadian rhythm maintenance: NAD+ oscillates with the circadian clock via the NAMPT enzyme. Disrupted NAD+ cycling correlates with metabolic syndrome markers. Keeping the pool topped up stabilizes circadian metabolic rhythms.
• Anti-inflammatory signaling: NAD+ depletion activates the NLRP3 inflammasome, promoting systemic inflammation that impairs insulin sensitivity. Repletion keeps this pathway in check.

From a practical standpoint, NAD+ is the metabolic insurance policy of this stack. Without it, the enhanced fat oxidation driven by Retatrutide and MOTS-C eventually outpaces the cofactor supply, and results stall.

The Synergy Model: Three Vectors, One Outcome

Here is how the three compounds interact:

Pathway	Retatrutide	MOTS-C	NAD+
Appetite suppression	Primary (GLP-1/GIP)	—	—
Hepatic fat oxidation	Primary (glucagon)	Supportive (AMPK)	Cofactor supply
Skeletal-muscle AMPK	—	Primary	Cofactor supply
Insulin sensitivity	Moderate (GIP)	Strong	Moderate (SIRT1)
Mitochondrial biogenesis	—	Moderate	Primary (SIRT1/PGC-1α)
Energy expenditure	Primary (glucagon)	Primary (AMPK)	Permissive (cofactor)

No single compound covers more than three of these six nodes. Together, all six are addressed. That is what mechanistic synergy looks like — not marketing language, but non-overlapping pharmacological coverage.

Structuring the Protocol: A Practical Framework

The following framework represents a common research approach. Individual response varies; adjustments should be made based on biomarkers and clinical observations.

Phase 1 — Weeks 1–4: Titration

• Retatrutide: 1 mg/week SC, increasing by 1 mg every two weeks (target: 4 mg/week by end of Phase 1).
• MOTS-C: 5 mg SC, 3×/week.
• NAD+: 100 mg IV or 250 mg sublingual daily.

The primary goal here is tolerability. GI side effects (nausea, reduced appetite) from Retatrutide are most pronounced during titration. Starting MOTS-C and NAD+ at full dose from day one establishes the metabolic foundation before Retatrutide reaches higher doses.

Phase 2 — Weeks 5–12: Full-Dose Optimization

• Retatrutide: 8–12 mg/week SC (dose depends on tolerability and body weight).
• MOTS-C: 5 mg SC, 5×/week (daily on training days + 2 rest days).
• NAD+: 250 mg IV weekly + 250 mg sublingual daily.

This is the peak fat-loss window. Appetite is significantly reduced (Retatrutide), mitochondrial throughput is maximized (MOTS-C + NAD+), and hepatic lipid oxidation is elevated (Retatrutide glucagon component). Most users report the steepest body-composition changes during weeks 6–10.

Phase 3 — Weeks 13–16: Consolidation

• Retatrutide: Maintain or reduce by 25 % based on goal weight proximity.
• MOTS-C: 5 mg SC, 3×/week (reduce to maintenance frequency).
• NAD+: Continue sublingual daily; IV sessions biweekly.

The consolidation phase focuses on metabolic set-point adjustment. Abruptly discon...